Response

To the Editor:
We appreciate the opportunity to respond to the comments of Dr. Reddy and Ms. Zaremba criticizing the perception of our "trumping" physician judgment. 1 By way of clarity, we wish to emphasize that our intent is in no way to undermine physician judgment (which we believe we are also exercising in drafting this commentary), but to point out that the cornerstone of good judgment, namely evidence, is lacking with regard to the justification of augmentation therapy for individuals with PI*MZ ␣ 1 -antitrypsin deficiency.
We lack clarity from reading Dr. Reddy's letter as to how our clinical commentary 1 undermines patients' access to specialists any more than the current economic adversity may, but appreciate and agree that access to the best medical information and clinicians is essential for the optimal care of individuals with ␣ 1 -antitrypsin deficiency. We suspect that in our current economic climate, patients' precious dollars should be spent first on a visit to a well-informed physician before prescribing for them a treatment the efficacy of which in the specific setting of PI*MZ ␣ 1 -antitrypsin deficiency lacks support and could contribute significant expense to the frail health-care system funding in our country. We contend that, in summarizing existing knowledge and its important gaps, our position in the clinical commentary 1 facilitates informed judgment, and we applaud the leadership of CHEST for its careful and critical review of the material. 
Diffusing Capacity and Alveolar Volume
To the Editor:
In discussing the diffusing capacity of the lung for carbon monoxide (Dlco), Dr. Plummer 1 points out the difficulty in "normalizing" the value with the alveolar volume (VA) because the relation between the two is nonlinear. There is another difficulty with the Dlco/VA ratio. Lung volumes determined by plethysmography or nitrogen washout are usually done along with the diffusing capacity. Frequently, I have observed that the VA derived from helium or methane dilution is considerably smaller (ie, upwards of 1 L) than the total lung capacity derived from plethysmography, even in patients whose dead space volume would be expected to be normal. In such patients, the VA should equal the total lung capacity minus an assumed dead space volume (roughly 2 mL/kg). In patients whose Dlco is low, the use of a VA derived from dilution may result in a "normal" Dlco/VA. In such cases, I calculate Dlco/VA using the total lung capacity and an assumed dead space volume, to see whether this confirms a normal Dlco/VA, which may guide interpretation of the test. In an article in the "Topics in Practice Management" section in a recent issue of CHEST (September 2008) entitled "The Carbon Monoxide Diffusing Capacity," Plummer 1 correctly pointed out that lung diffusion capacity corrected for alveolar ventilation (Kco [or ratio of diffusing capacity of the lung for carbon monoxide (Dlco) to alveolar volume (VA)]) is not constant as VA changes. In fact, Dlco and Kco change with VA, as would be expected with membrane conduction varying linearly with surface area (VA 2/3 ) or with VA, and blood conduction not changing. 2 Thus, one can "volume correct" Dlco (Daco) and Kco (Kaco). The predicted Daco ϭ predicted Dlco (0.58 ϩ 0.42 VA/VAtlc) and predicted Kaco ϭ predicted Kco (0.42 ϩ 0.58 VA/VAtlc), where VA is the measured VA, and VAtlc is the predicted VA at total lung capacity (ie, the predicted total lung capacity Ϫ predicted dead space). 2 The percent predicted Daco equals the percent predicted Kaco and provides a good indication of the diffusion capacity of the lung corrected for lung volume.
Just as the predicted Dlco and Kco are adjusted for hemoglobin, the predicted Dlco and Kco should also be adjusted for lung volume. There are specific patterns of the percent predicted Dlco, Kco, VA, and Daco (or Kaco) among lung diseases. 2 While patients with interstitial lung disease often have a Dlco Ͻ 80% predicted and a Kco Ͼ 80% predicted, Daco and Kaco are low. While patients with extrapulmonary restriction but otherwise normal lungs often have low Dlco and elevated Kco levels, Daco and Kaco levels are normal. Patients with emphysema have low Dlco, Kco, Daco, and Kaco.
Dlco studies should go beyond reporting measured, predicted, and percent predicted Dlco, Kco, and VA. Predicted and percent predicted Dlco adjusted for lung volume (ie, Daco) and Kco adjusted for lung volume (ie, Kaco) should also be reported.
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